| Patient | Zora Neale Hurston |
|---|---|
| Date of birth | 1891-01-07 |
| Identifiers | MRN HR-ML040-SYN-TD; SSN (made up) 000-40-6213 |
| Document date | 1958-04-06 |
| Author | Lorraine Abernathy-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review after starting dapagliflozin. [S]
Ms. Hurston returns two weeks after starting dapagliflozin and atorvastatin. She is less breathless: she now climbs the stairs at the school without stopping, and her ankles no longer swell by evening. Her home blood pressure average this week is 134/82. She has had no lightheadedness, genital itching or burning on passing urine, and no muscle aches. She weighs herself each morning. Her SNAP benefits were approved, the patient assistance program shipped a 90-day supply of dapagliflozin, and the SHINE counselor helped her apply for Extra Help and the Medicare Savings Program. She can name the BE FAST signs and keeps the card by her telephone. [S]
| Element | Detail |
|---|---|
| Home blood pressure | Average 134/82 mmHg |
| Symptoms | Stairs at school without stopping; ankle swelling gone |
| Medicine effects | No lightheadedness, genital infection or muscle aches |
| Benefits | SNAP approved; Extra Help and Medicare Savings Program applications submitted |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling; breathless only on hurrying |
| Genitourinary | Negative | No genital itching or dysuria |
| Musculoskeletal | Negative | No muscle aches or cramps |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 5 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 1958-03-09 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morning | One-half tablet every morning | Oral route | 1958-03-09 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 1958-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1958-03-23 | active | S |
| Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily | One-half tablet daily | Oral route | 1958-04-06 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1958-04-06 | Body height | 165 | cm | S |
| 1958-04-06 | Body weight | 82.6 | kg | S |
| 1958-04-06 | Body mass index (BMI) [Ratio] | 30.3 | kg/m2 | S |
| 1958-04-06 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1958-04-06 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1958-04-06 | Heart rate | 76 | /min | S |
| 1958-04-06 | Respiratory rate | 16 | /min | S |
| 1958-04-06 | Body temperature | 36.7 | Cel | S |
| 1958-04-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1958-04-06 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1958-04-06 | Potassium [Moles/volume] in Serum or Plasma | 3.4 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 1958-04-06 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1958-04-06 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1953)/1.73 sq M | 63 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1958-04-06 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1958-04-06 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
Vital signs recorded on 1958-04-06; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 134/82, pulse 76; weight 82.6 kg |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; S4 |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Very high blood pressure at intake (178/104 and 174/102 mmHg) with morning headaches for two months, without signs of a hypertensive emergency; not previously diagnosed; ambulatory monitoring to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting problem, resolved when ambulatory monitoring and the echocardiogram established the diagnosis at the second visit. Not a claim about her real blood pressure. |
| Breathlessness on exertion for three months (walking to the school, carrying groceries) with mild ankle swelling by evening; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved into the heart failure diagnosis at the second visit. |
| Hypertensive heart disease with heart failure: stage 2 hypertension confirmed by 24-hour ambulatory monitoring (mean 158/96 mmHg, non-dipping at night), with concentric left ventricular hypertrophy on ECG and echocardiogram; synthetic modern episode linked to the hypertensive heart disease recorded as her cause of death | active | confirmed | I11.0 | S — Synthetic modern diagnosis made at the second visit; the 1960 cause of death remains D. |
| Heart failure with preserved ejection fraction (ejection fraction 62%), NYHA class II, with grade II diastolic dysfunction and an enlarged left atrium | active | confirmed | I50.32 | S — Synthetic modern diagnosis confirmed by echocardiogram and cardiology at the second visit. |
| Food insecurity: food runs short at the end of most months (Hunger Vital Sign positive) | active | confirmed | Z59.41 | S — Synthetic social need anchored to her documented poverty. |
| Low and irregular income from substitute teaching and newspaper writing, with Original Medicare but no drug coverage; medicine costs a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented low income in the 1950s. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure in the clinic (seated, average of two readings, large cuff) | Every visit | Completed today | 134/82 mmHg |
| Examination | Out-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes) | At diagnosis and with each treatment change | Completed today | Home average 134/82 mmHg |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 82.6 kg; jugular venous pressure not raised; no edema; NYHA I to II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six months | Completed today | Two weeks after dapagliflozin: sodium 137, potassium 3.4 (low), creatinine 0.98 mg/dL (eGFR 63), magnesium 1.8 |
| Medication safety | SGLT2 inhibitor: genital infection, volume depletion and sick-day rules | Every visit | Completed today | No genital infection or lightheadedness; sick-day rules reviewed |
| Imaging | ECG and echocardiogram | At diagnosis; repeat only with unexplained clinical change | Not indicated | Diagnosis made two weeks ago; no clinical change |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Up to date | 54 at diagnosis; next at about three months |
| Laboratory | Lipid panel | Four to twelve weeks after starting a statin; then yearly | Up to date | Two weeks on atorvastatin; panel at the next visit |
| Self-management | Self-care: daily weights, less salt, sick-day rules and the BE FAST stroke signs | Every visit | Completed today | Weighs daily; less salt at the table; teaches back the BE FAST signs |
| Medication safety | Medicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program) | Every visit | Completed today | Dapagliflozin 90-day supply from patient assistance; Extra Help and Medicare Savings Program applications submitted |
| Self-management | Food access | Every visit | Completed today | SNAP approved |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026); Signs and Symptoms of Stroke (2026); Help with drug costs (Extra Help) (2026); Medicare Savings Programs (2026); SNAP Eligibility (2026)
Follow-up: Metabolic panel in one to two weeks at the clinic laboratory. Review in eight weeks with a metabolic panel, lipid panel and the KCCQ-12. Next scheduled visit 1958-06-01: eight-week review: blood pressure at home and in the clinic, potassium and kidney function, lipids, KCCQ-12 and drug coverage. [S]